nach oben

Current Fungal Infection Reports

Erschienen in:

02.03.2018 | Pediatric Fungal Infections (E Roilides, Section Editor)

Antifungal Prophylaxis in Children Receiving Antineoplastic Chemotherapy

verfasst von: Elio Castagnola, Alessio Mesini

Erschienen in: Current Fungal Infection Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the review

The purpose of this study was to summarize data on available antifungal prophylaxis of invasive fungal disease (IFD) in children and when it should be administered during antineoplastic chemotherapy.

Recent findings

Antifungal prophylaxis should be considered when incidence of IFD is ≥ 10%, as acute myeloblastic leukemia, high-risk acute lymphoblastic leukemia, and second-line therapy for any relapsing leukemia. In absence of specific pediatric studies, data from adults indicate that triazoles, especially posaconazole tablets, could represent the most attractive option, even if some troubles (mainly regarding drug interactions and intestinal absorption) must be underlined. Echinocandins and liposomal amphotericin B (intravenous or nebulized) can represent alternatives in specific conditions. Other infection control measures (hand hygiene, respiratory masks) can represent adjunctive and effective measures.

Summary

Antifungal prophylaxis should be implemented in children receiving aggressive chemotherapy for acute leukemia, and triazoles represent the first choice for this purpose.

Cesaro S, Tridello G, Castagnola E, Calore E, Carraro F, Mariotti I, et al. Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients. Eur J Haematol. 2017;99:240–8.CrossRefPubMed

Steinbach WJ, Roilides E, Berman D, Hoffman JA, Groll AH, Bin-Hussain I, et al. Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates. Pediatr Infect Dis J. 2012;31:1252–7.CrossRefPubMed

Wattier RL, Dvorak CC, Hoffman JA, Brozovich AA, Bin-Hussain I, Groll AH, et al. A prospective, international cohort study of invasive mold infection in children. J Pediatr Infect Dis Soc. 2015;4:313–22.CrossRef

Zajac-Spychala O, Gowin E, Fichna P, et al. Pneumocystis pneumonia in children - the relevance of chemoprophylaxis in different groups of immunocompromised and immunocompetent paediatric patients. Cent Eur J Immunol. 2015;40:91–5.CrossRefPubMedPubMedCentral

Caselli D, Petris MG, Rondeli R, et al. Single-day trimethoprim/sulfamethoxazole prophylaxis for pneumocystis pneumonia in children with cancer. J Pediatr. 2014;164:389–92.CrossRefPubMed

Castagnola E, Bagnasco F, Bandettini R, et al. Role of acute graft-versus-host disease in the risk of bacteremia and invasive fungal disease after allogeneic Hemopoietic stem cell transplantation in children. Results from a single-center observational study. Biol Blood Marrow Transplant. 2014;20:1056–73.CrossRef

Castagnola E, Cesaro S, Giacchino M, Livadiotti S, Tucci F, Zanazzo G, et al. Fungal infections in children with cancer: a prospective, multicenter surveillance study. Pediatr Infect Dis J. 2006;25:634–9.CrossRefPubMed

Fisher BT, Robinson PD, Lehrnbecher T, Steinbach WJ, Zaoutis TE, Phillips B, et al. Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review. J Pediatric Infect Dis Soc. 2017; https://doi.org/10.1093/jpids/pix030.

Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC. Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol. 2010;149:263–72.CrossRefPubMed

10.

Sung L, Gamis A, Alonzo TA, Buxton A, Britton K, DeSwarte-Wallace J, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009;115:1100–8.CrossRefPubMedPubMedCentral

11.

Styczynski J, Czyzewski K, Wysocki J, et al. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clin Microbiol Infect. 2016;22:179–88.CrossRefPubMed

12.

Castagnola E, Bagnasco F, Amoroso L, Caviglia I, Caruso S, Faraci M, et al. Role of management strategies in reducing mortality from invasive fungal disease in children with cancer or receiving hemopoietic stem cell transplant: a single center 30-year experience. Pediatr Infect Dis J. 2014;33:233–7.CrossRefPubMed

13.

McQuay HJ, Moore RA. Issues involved in making choices in prophylaxis. Ann Intern Med. 1997;126:712–20.CrossRefPubMed

14.

Castagnola E, Rossi MR, Cesaro S, Livadiotti S, Giacchino M, Zanazzo G, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer. 2010;55:1103–7.CrossRefPubMed

15.

De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis--has the principle been proven? N Engl J Med. 2007;356:409–11.CrossRefPubMed

16.

Tatarelli P, Faraci M, Caviglia I, Bandettini R, Cangemi G, Magnano GM, et al. Epidemiology of invasive fungal diseases in children with solid tumours undergoing autologous haematopoietic stem cell transplantation: a 10-year experience in a tertiary Italian centre. Mycoses. 2017;60:517–20.CrossRefPubMed

17.

Castagnola E, Fontana V, Caviglia I, Caruso S, Faraci M, Fioredda F, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1296–304.CrossRefPubMed

18.

Castagnola E, Caviglia I, Pistorio A, Fioredda F, Micalizzi C, Viscoli C, et al. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer. 2005;41:1439–45.CrossRefPubMed

19.

Haupt R, Romanengo M, Fears T, Viscoli C, Castagnola E. Incidence of septicaemias and invasive mycoses in children undergoing treatment for solid tumours: a 12-year experience at a single Italian institution. Eur J Cancer. 2001;37:2413–9.CrossRefPubMed

20.

Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol. 2001;54:253–62.CrossRefPubMed

21.

Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44:1283–97.CrossRefPubMed

22.

Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, et al. Fourth European conference on infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15:e327–40.CrossRefPubMed

23.

Lehrnbecher T. Antifungal prophylaxis in pediatric patients undergoing therapy for cancer: drugs and dosing. Curr Opin Infect Dis. 2015;28:523–31.CrossRefPubMed

24.

Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2005;36:621–9.CrossRefPubMed

25.

Lai HP, Chen YC, Chang LY, Lu CY, Lee CY, Lin KH, et al. Invasive fungal infection in children with persistent febrile neutropenia. J Formos Med Assoc. 2005;104:174–9.PubMed

26.

Mor M, Gilad G, Kornreich L, Fisher S, Yaniv I, Levy I. Invasive fungal infections in pediatric oncology. Pediatr Blood Cancer. 2011;56:1092–7.CrossRefPubMed

27.

Tragiannidis A, Dokos C, Lehrnbecher T, Groll AH. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice. Drugs. 2012;72:685–704.CrossRefPubMed

28.

Lanciotti M, Pigullo S, Lanza T, Dufour C, Caviglia I, Castagnola E. Possible role of toll-like receptor 9 polymorphism in chemotherapy-related invasive mold infections in children with hematological malignancies. Pediatr Blood Cancer. 2008;50:944.CrossRefPubMed

29.

Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med. 2008;359:1766–77.CrossRefPubMedPubMedCentral

30.

Koldehoff M, Beelen DW, Elmaagacli AH. Increased susceptibility for aspergillosis and post-transplant immune deficiency in patients with gene variants of TLR4 after stem cell transplantation. Transpl Infect Dis. 2013;15:533–9.PubMed

31.

Fischer M, Spies-Weisshart B, Schrenk K, Gruhn B, Wittig S, Glaser A, et al. Polymorphisms of Dectin-1 and TLR2 predispose to invasive fungal disease in patients with acute myeloid leukemia. PLoS One. 2016;11:e0150632.CrossRefPubMedPubMedCentral

32.

Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics. 2006;117:e711–6.CrossRefPubMed

33.

Crassard N, Hadden H, Piens MA, Pondarré C, Hadden R, Galambrun C, et al. Invasive aspergillosis in a paediatric haematology department: a 15-year review. Mycoses. 2008;51:109–16.CrossRefPubMed

34.

Castagnola E, Conte M, Parodi S, Papio F, Caviglia I, Haupt R. Incidence of Bacteremias and invasive mycoses in children with high risk neuroblastoma. Pediatr Blood Cancer. 2007;49:672–7.CrossRefPubMed

35.

Stergiopoulou T, Walsh TJ. Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients. Expert Opin Pharmacother. 2015;16:213–26.CrossRefPubMed

36.

Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69:1162–76.CrossRefPubMed

37.

Science M, Robinson PD, MacDonald T, Rassekh SR, Dupuis LL, Sung L. Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2014;61:393–400.CrossRefPubMed

38.

Doering M, Cabanillas Stanchi KM, Queudeville M, et al. Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2017;143:1281–92.CrossRef

39.

Vanstraelen K, Colita A, Bica AM, Mols R, Augustijns P, Peersman N, et al. Pharmacokinetics of Posaconazole oral suspension in children dosed according to body surface area. Pediatr Infect Dis J. 2016;35:183–8.CrossRefPubMed

40.

Green MR, Woolery JE. Optimising absorption of posaconazole. Mycoses. 2011;54:e775–9.CrossRefPubMed

41.

Zembles TN, Thompson NE, Havens PL, Kaufman BA, Huppler AR. An optimized Voriconazole dosing strategy to achieve therapeutic serum concentrations in children younger than 2 years old. Pharmacotherapy. 2016;36:1102–8.CrossRefPubMed

42.

Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–51.CrossRefPubMed

43.

Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545–52.CrossRefPubMed

44.

Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138:705–13.CrossRefPubMed

45.

Pana ZD, Kourti M, Vikelouda K, et al. Voriconazole antifungal prophylaxis in children with malignancies: a Nationwide study. J Pediatr Hematol Oncol. 2018;40:22–6.PubMed

46.

Maron GM, Hayden RT, Rodriguez A, Rubnitz JE, Flynn PM, Shenep JL, et al. Voriconazole prophylaxis in children with cancer: changing outcomes and epidemiology of fungal infections. Pediatr Infect Dis J. 2013;32:e451–5.CrossRefPubMed

47.

Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59.CrossRefPubMed

48.

Cesaro S, Milano GM, Aversa F. Retrospective survey on the off-label use of posaconazole in pediatric hematology patients. Eur J Clin Microbiol Infect Dis. 2011;30:595–6.CrossRefPubMed

49.

Vicenzi EB, Calore E, Decembrino N, Berger M, Perruccio K, Carraro F, et al. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients. Eur J Haematol. 2017;100:315–22. https://doi.org/10.1111/ejh.13017.CrossRef

50.

Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335–47.CrossRefPubMed

51.

Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53:958–66.CrossRefPubMed

52.

Gwee A, Cranswick N, Curtis N. Posaconazole: promising but problematic in practice in pediatric patients. Pediatr Infect Dis J. 2015;34:604–6.CrossRefPubMed

53.

European, Medicine, Agency. Posaconazole Summary of Product Characteristics. In.

54.

Chau MM, Kong DC, van Hal SJ, et al. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Intern Med J. 2014;44:1364–88.CrossRefPubMed

55.

Allegra S, Fatiguso G, De Francia S, et al. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. Br J Clin Pharmacol. 2018;84:197–203.CrossRefPubMed

56.

Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TCG, Ververs TT, et al. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013;57:235–40.CrossRefPubMedPubMedCentral

57.

Boast A, Curtis N, Cranswick N, Gwee A. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre. J Antimicrob Chemother. 2016;71:2031–6.CrossRefPubMed

58.

Dote S, Sawai M, Nozaki A, Naruhashi K, Kobayashi Y, Nakanishi H. A retrospective analysis of patient-specific factors on voriconazole clearance. J Pharm Health Care Sci. 2016;2:10.CrossRefPubMedPubMedCentral

59.

van Wanrooy MJ, Span LF, Rodgers MG, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58:7098–101.CrossRefPubMedPubMedCentral

60.

Veringa A, Ter Avest M, Span LF, et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 2017;72:261–7.CrossRefPubMed

61.

Wallace KL, Filipek RL, La Hoz RM, Williamson JC. Subtherapeutic voriconazole concentrations associated with concomitant dexamethasone: case report and review of the literature. J Clin Pharm Ther. 2016;41:441–3.CrossRefPubMed

62.

Bruggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441–58.CrossRefPubMed

63.

van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–16.CrossRefPubMed

64.

Doring M, Hartmann U, Erbacher A, et al. Caspofungin as antifungal prophylaxis in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective analysis. BMC Infect Dis. 2012;12:151.CrossRefPubMedPubMedCentral

65.

Bochennek K, Tramsen L, Schedler N, Becker M, Klingebiel T, Groll AH, et al. Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. Clin Microbiol Infect. 2011;17:1868–74.CrossRefPubMed

66.

Hullard-Pulstinger A, Holler E, Hahn J, Andreesen R, Krause SW. Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia. Onkologie. 2011;34:254–8.CrossRefPubMed

67.

Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al. ECIL guidelines for preventing pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2397–404.CrossRefPubMed

68.

Dallorso S, Castagnola E, Garaventa A, Rossi GA, Giacchino R, Dini G. Early onset of pneumocystis carinii pneumonia in a patient receiving bone marrow transplantation from a matched unrelated donor. Bone Marrow Transplant. 1994;13:106–7.PubMed

69.

Castagnola E, Zarri D, Caprino D, Losurdo G, Micalizzi C. Cotrimoxazole prophylaxis of pneumocystis carinii infection during the treatment of childhood acute lymphoblastic leukemia--beware non compliance in older children and adolescents. Support Care Cancer. 2001;9:552–3.CrossRefPubMed

70.

Sung L, Nathan PC, Lange B, Beyene J, Buchanan GR. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22:3350–6.CrossRefPubMed

71.

Sung L, Aplenc R, Alonzo TA, Gerbing RB, Lehrnbecher T, Gamis AS. Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's oncology group. Blood. 2013;121:3573–7.CrossRefPubMedPubMedCentral

72.

Delfino D, Scordino F, Pernice I, Lo Passo C, Galbo R, David A, et al. Potential association of specific Candida Parapsilosis genotypes, bloodstream infections and colonization of health workers' hands. Clin Microbiol Infect. 2014;20:O946–51.CrossRefPubMed

73.

Yildirim M, Sahin I, Kucukbayrak A, et al. Hand carriage of Candida species and risk factors in hospital personnel. Mycoses. 2007;50:189–92.CrossRefPubMed

74.

Storti LR, Pasquale G, Scomparim R, Galastri AL, Alterthum F, Gambale W, et al. Candida spp. isolated from inpatients, the environment, and health practitioners in the pediatric unit at the Universitary Hospital of the Jundiai Medical College, state of Sao Paulo, Brazil. Rev Soc Bras Med Trop. 2012;45:225–31.CrossRefPubMed

75.

WHO Guidelines Approved by the Guidelines Review Committee. In WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. Geneva: World Health Organization 2009.

76.

Yildirim M, Sahin I, Oksuz S, Sencan I, Kucukbayrak A, Cakir S, et al. Hand carriage of Candida occurs at lesser rates in hospital personnel who use antimicrobial hand disinfectant. Scand J Infect Dis. 2014;46:633–6.CrossRefPubMed

77.

Zakhour R, Chaftari AM, Raad II. Catheter-related infections in patients with haematological malignancies: novel preventive and therapeutic strategies. Lancet Infect Dis. 2016;16:e241–50.CrossRefPubMed

78.

Zakhour R, Hachem R, Alawami HM, Jiang Y, Michael M, Chaftari AM, et al. Comparing catheter-related bloodstream infections in pediatric and adult cancer patients. Pediatr Blood Cancer. 2017;64

79.

Lo Vecchio A, Schaffzin JK, Ruberto E, Caiazzo MA, Saggiomo L, Mambretti D, et al. Reduced central line infection rates in children with leukemia following caregiver training: a quality improvement study. Medicine (Baltimore). 2016;95:e3946.CrossRef

80.

Castagnola E, Viscoli C. Invasive aspergillosis in malignancy and stem cell transplant recipients. In: Largè JP, Steinbach WJ, editors. Aspergillus fumigatus and aspergillosis. Washington: ASM Press; 2009. p. 519–30.CrossRef

81.

Benet T, Nicolle MC, Thiebaut A, Piens MA, Nicolini FE, Thomas X, et al. Reduction of invasive aspergillosis incidence among immunocompromised patients after control of environmental exposure. Clin Infect Dis. 2007;45:682–6.CrossRefPubMed

82.

Pokala HR, Leonard D, Cox J, Metcalf P, McClay J, Siegel J, et al. Association of hospital construction with the development of healthcare associated environmental mold infections (HAEMI) in pediatric patients with leukemia. Pediatr Blood Cancer. 2014;61:276–80.CrossRefPubMed

83.

Hahn T, Cummings KM, Michalek AM, Lipman BJ, Segal BH, McCarthy PL. Efficacy of high-efficiency particulate air filtration in preventing aspergillosis in immunocompromised patients with hematologic malignancies. Infect Control Hosp Epidemiol. 2002;23:525–31.CrossRefPubMed

84.

Humphreys H. Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence? J Hosp Infect. 2004;56:93–100. quiz 163CrossRefPubMed

85.

Berthelot P, Loulergue P, Raberin H, Turco M, Mounier C, Tran Manh Sung R, et al. Efficacy of environmental measures to decrease the risk of hospital-acquired aspergillosis in patients hospitalised in haematology wards. Clin Microbiol Infect. 2006;12:738–44.CrossRefPubMed

86.

Cornet M, Levy V, Fleury L, Lortholary J, Barquins S, Coureul MH, et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol. 1999;20:508–13.CrossRefPubMed

87.

Maschmeyer G, Neuburger S, Fritz L, Bohme A, Penack O, Schwerdtfeger R, et al. A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol. 2009;20:1560–4.CrossRefPubMed

88.

Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Summerbell RC, Rex JH, et al. Pathogenic molds (including aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood. 2003;101:2542–6.CrossRefPubMed

Titel: Antifungal Prophylaxis in Children Receiving Antineoplastic Chemotherapy
verfasst von: Elio Castagnola
Alessio Mesini
Publikationsdatum: 02.03.2018
Verlag: Springer US
Erschienen in: Current Fungal Infection Reports / Ausgabe 2/2018
Print ISSN: 1936-3761
Elektronische ISSN: 1936-377X
DOI: https://doi.org/10.1007/s12281-018-0311-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Purpose of the review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Prevention of Invasive Candidiasis in Premature Neonates: Administering Fluconazole or Not?

Candidiasis of the Central Nervous System in Neonates and Children With Primary Immunodeficiencies

PCR-Based Methods for the Diagnosis of Invasive Candidiasis: Are They Ready for Use in the Clinic?

Fungal Eye Infections: New Hosts, Novel Emerging Pathogens but No New Treatments?